Nurix Therapeutics CLO sells shares for tax cover

Nurix Therapeutics, Inc. reported insider activity by Chief Legal Officer Christine Ring on July 30, 2026.

Rhea-AI Filing Summary

Nurix Therapeutics, Inc. reported insider activity by Chief Legal Officer Christine Ring on July 30, 2026. Three RSU tranches of 3,750, 2,858, and 3,572 units (total 10,180) vested and converted into the same number of common shares at a $0.00 exercise price. On the same date, 3,847 common shares were sold at a weighted average price of $23.3828 per share to cover tax withholding obligations through a mandatory “sell to cover” mechanism under the issuer’s equity plans, and the filing notes these were not discretionary trades.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 7 txns

Insider Ring Christine

Role Chief Legal Officer

Sold 3,847 shs ($90K)

Approx. gross sale proceeds $90K

Approx. exercise cost $0.00

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units F3, F4, F5	3,750	$0.00	$0.00
Exercise	Restricted Stock Units F3, F6, F5	2,858	$0.00	$0.00
Exercise	Restricted Stock Units F3, F7, F5	3,572	$0.00	$0.00
Exercise	Common Stock	3,750	$0.00	$0.00
Exercise	Common Stock	2,858	$0.00	$0.00
Exercise	Common Stock	3,572	$0.00	$0.00
Sale	Common Stock F1, F2	3,847	$23.3828	$90K

Holdings After Transaction: Restricted Stock Units — 70,562 contracts (Direct); Common Stock — 19,912 shares (Direct)

Footnotes (7)

1. F1. The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
2. F2. Represents the weighted average sale price. The lowest price at which shares were sold was $23.00 and the highest price at which shares were sold was $23.90. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
3. F3. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
4. F4. The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
5. F5. RSUs do not expire; they either vest or are canceled prior to the vest date.
6. F6. The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2025, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
7. F7. The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2026, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

Key Figures

Common shares sold: 3,847 shares Weighted average sale price: $23.3828 per share RSUs converted (tranche 1): 3,750 shares +3 more

6 metrics

Common shares sold 3,847 shares Common stock sold on July 30, 2026 to cover tax withholding

Weighted average sale price $23.3828 per share Price for 3,847 common shares sold; range $23.00–$23.90

RSUs converted (tranche 1) 3,750 shares RSUs vesting quarterly over three years from initial vest date July 30, 2024

RSUs converted (tranche 2) 2,858 shares RSUs vesting quarterly over three years from initial vest date July 30, 2025

RSUs converted (tranche 3) 3,572 shares RSUs vesting quarterly over three years from initial vest date July 30, 2026

Total RSUs converted 10,180 shares Sum of three RSU tranches (3,750; 2,858; 3,572) exercised on July 30, 2026

Key Terms

Restricted Stock Units, sell to cover, weighted average sale price

3 terms

Restricted Stock Units financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

sell to cover financial

"tax withholding obligations to be funded by a "sell to cover" transaction"

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

weighted average sale price financial

"Represents the weighted average sale price. The lowest price at which shares were sold"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Nurix Therapeutics (NRIX) report for Christine Ring?

Nurix Therapeutics reported that Chief Legal Officer Christine Ring had 10,180 RSUs vest and convert into common stock, and 3,847 common shares were sold on July 30, 2026 to satisfy tax withholding obligations via a mandatory “sell to cover” arrangement.

How many Nurix Therapeutics (NRIX) shares did Christine Ring sell and at what price?

Christine Ring sold 3,847 common shares of Nurix Therapeutics at a weighted average price of $23.3828 per share. A footnote explains the sale price ranged between $23.00 and $23.90, and the transactions were executed solely to cover tax withholding obligations.

What RSU awards vested for Nurix Therapeutics (NRIX) Chief Legal Officer on July 30, 2026?

On July 30, 2026, three RSU awards vested for Christine Ring, converting 3,750, 2,858, and 3,572 restricted stock units into the same number of common shares. Each RSU represents a contingent right to receive one share of Nurix Therapeutics common stock upon vesting.

Were the Nurix Therapeutics (NRIX) share sales by Christine Ring discretionary trades?

No. A footnote states the 3,847-share sale was required to cover tax withholding obligations tied to RSU vesting and resulted from the issuer’s election to use a “sell to cover” mechanism, meaning the transactions did not represent discretionary trades by Christine Ring.

How are Christine Ring’s RSUs at Nurix Therapeutics (NRIX) structured to vest?

Footnotes explain that each RSU grant vests as to 1/12 of the total award quarterly over three years, with first vesting dates on July 30 of 2024, 2025, or 2026, respectively, subject to her continued service, after which common shares are delivered.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/30/2026 - 05:56 PM Accepted by SEC EDGAR 07/30/2026 - 05:56 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ring Christine

(Last) (First) (Middle)

C/O NURIX THERAPEUTICS, INC.

1600 SIERRA POINT PKWY

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nurix Therapeutics, Inc. [ NRIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/30/2026		M		3,750	A	$0	17,329	D
Common Stock	07/30/2026		M		2,858	A	$0	20,187	D
Common Stock	07/30/2026		M		3,572	A	$0	23,759	D
Common Stock	07/30/2026		S(1)		3,847	D	$23.3828(2)	19,912	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0(3)	07/30/2026		M			3,750	(4)	(5)	Common Stock	3,750	$0	11,250	D
Restricted Stock Units	$0(3)	07/30/2026		M			2,858	(6)	(5)	Common Stock	2,858	$0	20,009	D
Restricted Stock Units	$0(3)	07/30/2026		M			3,572	(7)	(5)	Common Stock	3,572	$0	39,303	D

Explanation of Responses:

1. The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

2. Represents the weighted average sale price. The lowest price at which shares were sold was $23.00 and the highest price at which shares were sold was $23.90. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

3. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

4. The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

5. RSUs do not expire; they either vest or are canceled prior to the vest date.

6. The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2025, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

7. The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2026, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

Remarks:

	/s/ Daniel Burbach, as Attorney-in-Fact for Christine Ring	07/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)